ChinaBio Today -- IMS Health (NYSE: IMS) has upped its count of “pharmerging” countries to 17 high-growth pharmaceutical markets (see story). Previously, only seven markets qualified. According to IMS Health, these 17 countries represent $90 billion of increased pharmaceutical spending during 2009-13, collectively offering 48% of the growth in the worldwide market in 2013. China is the most significant opportunity of the 17, a market that is “in a league of its own” in the words of the healthcare consultancy company.
